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Objective:  Myeloid cells, including macrophages and dendritic cells, are a prominent component of central 
nervous system (CNS) infiltrates during multiple sclerosis (MS) and the animal model experimental 
autoimmune encephalomyelitis (EAE).  Although myeloid cells are generally thought to be pro-inflammatory, 
alternatively-polarized subsets can serve non-inflammatory and/or reparative functions.  Here we investigate 
the heterogeneity and biological properties of myeloid cells during central nervous system autoimmunity.  
Methods: Myeloid cell phenotypes in chronic active MS lesions were analyzed by immunohistochemistry.  In 
addition, immune cells were isolated from the CNS during exacerbations and remissions of EAE and 
characterized by flow cytometric, genetic and functional assays.  Results:  Myeloid cells expressing iNOS, 
indicative of a pro-inflammatory phenotype, were detected in the actively demyelinating rim of chronic active 
MS lesions, whereas macrophages expressing mannose receptor (CD206), a marker of alternatively-
polarized human myeloid cells, were enriched in the quiescent lesion core.  During EAE, CNS-infiltrating 
myeloid cells, as well as microglia, shifted from expression of pro- to non-inflammatory markers immediately 
prior to clinical remissions.  Murine CNS myeloid cells expressing the alternative lineage marker arginase-1 
(Arg1) were partially derived from iNOS
+
 precursors and were deficient in activating encephalitogenic T cells 
compared with their Arg1
-
 counterparts.  Interpretation:  These observations demonstrate the heterogeneity 
of CNS myeloid cells, their evolution during the course of autoimmune demyelinating disease, and their 
plasticity on the single cell level.  Future therapeutic strategies for disease modification in individuals with MS 
may be focused on accelerating the transition of CNS myeloid cells from a pro- to a non-inflammatory 
phenotype. 
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INTRODUCTION 
Myeloid cells, including macrophages (MΦ) and dendritic cells (DC), are a major component of white 
matter lesions in multiple sclerosis (MS) and the animal model experimental autoimmune encephalomyelitis 
(EAE)
1,2
.  Our laboratory and others have established a critical role of myeloid cells in early EAE 
pathogenesis
3–6
.  Myeloid cells may serve as antigen presenting cells for re-activation of myelin-specific CD4
+
 
T cells
7,8
, secrete cytokines such as IL-6, IL-1β, and TNFα
9
, and directly inflict damage through release of 
toxic factors such as reactive oxygen species generated by inducible nitric oxide synthase (iNOS)
10,11
.  iNOS-
expressing myeloid cells are often described as classically-activated, and considered “pro-inflammatory”, 
based on their similarity to bone marrow derived macrophages (BMDM) polarized with LPS or IFNγ in vitro
12
.  
It is generally thought that classically-activated myeloid cells (CAMC) are predominant in active MS and EAE 
lesions where they act as pathogenic effector cells
13–15
.  Early studies of autopsied MS brains revealed iNOS-
immunoreactive macrophages in active lesions
14,16,17
. The presence of iNOS
+
 myeloid cells generally 
correlated with zones of ongoing demyelination.  
However, there is growing evidence that myeloid cells that accumulate in the central nervous system 
(CNS) are heterogeneous and likely encompass a spectrum of lineages with diverse, and even opposing, 
properties
18–20
.  In contrast to iNOS, the enzyme arginase-1 (Arg1) and the mannose receptor CD206 have 
been identified as markers of myeloid cells with “immunosuppressive” or “pro-regenerative” properties.  
Arg1/CD206-expressing myeloid cells play a critical role in wound healing
21
.  They are frequently classified as 
alternatively-activated based on their similarity to BMDM generated in vitro by polarization with IL-4 or IL-13 
via a STAT6-dependent pathway
12,22
.  Alternatively-activated myeloid cells (AAMC) may regulate the 
inflammatory environment by secreting IL-10 and/or TGFβ1
9
, while promoting tissue regeneration by clearing 
debris
23,24
 and secreting growth factors
25
.  Foamy (lipid-laden) macrophages, perivascular macrophages, and 
microglia expressing human AAMC markers, such as CD206 and CD163, have been discovered in acute and 
chronic active MS lesions
2,19,25,26
.  Primary human macrophages acquire a foamy morphology and produce 
immunosuppressive factors following ingestion of myelin in vitro
19
.   
We questioned whether CNS myeloid cells evolve during disease progression and shift from a pro-
inflammatory phenotype at onset to a non-inflammatory or immunosuppressive state in anticipation of clinical 
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AAMC-associated genes Arg1, Chi3l3 and Ms4a8a at the peak of EAE, shortly prior to remission
27
.  In fact, 
Arg1 is the most-significantly up-regulated gene in the CNS at peak EAE
28
.  Adoptive transfer of AAMC- 
polarized macrophages or microglia can ameliorate EAE
29,30
, and the therapeutic effects of estrogen, 
glatiramer acetate and other agents in EAE were found to correlate with the expansion of AAMC in the 
periphery and/or CNS
31–34
.  Less is known about endogenous AAMC that spontaneously accumulate in the 
CNS during the course of EAE or MS.  In the current paper, we compare the spatial distribution of AAMC in 
actively demyelinating and quiescent regions of MS lesions.  In addition, we examine the origin, kinetics and 
biological properties of CNS myeloid subsets from the preclinical stage of EAE through peak and remission. 
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METHODS 
Mice.  C57Bl/6 and B6.Ly5.1 mice were from Charles River Laboratories.  Arg1-eYFP
35
, Rosa-LSL-eYFP, 
2D2 TCR transgenic, and STAT6
-/-
 mice were from the Jackson Laboratory.  iNOS-TdTomato-Cre
36
 mice 
were from the European Mouse Mutant Archive.  SJL mice were from Harlan Laboratory.  Both male and 
female mice, age 6-12 weeks, were used in experiments.  All mice were bred and maintained under specific 
pathogen-free conditions at the University of Michigan, and all animal experiments were performed in 
accordance with an IACUC-approved protocol at the University of Michigan. 
 
Induction and assessment of EAE.  For active immunization, C57Bl/6 mice were subcutaneously immunized 
over the flanks with 100 µg MOG35-55 (Biosythesis) in complete Freund’s adjuvant (Difco).  Mice were injected 
intraperitoneally with 300 ng pertussis toxin (List Biological) on days 0 and 2.  For adoptive transfer, mice 
were immunized as described, without pertussis toxin, and the draining lymph nodes (inguinal, brachial, and 
axillary) were collected at 10-14 days post-immunization.  Lymph node cells were cultured for 96 hours in the 
presence of 50 ug/mL MOG35-55, 8 ng/ml IL-23 (R&D Systems), 10 ng/ml IL-1α (Peprotech), and 10 µg/mL 
anti-IFNγ (Clone XMG1.2, BioXcell).  At the end of culture, CD4
+
 T cells were purified with CD4 positive 
selection magnetic beads (Miltenyi), and 3-5x10
6
 CD4
+
 T cells were transferred intraperitoneally into naïve 
recipients.  For induction of relapsing-remitting EAE, SJL mice were subcutaneously immunized over the 
flanks with 100 µg PLP139-151 (Biosynthesis) in complete Freund’s adjuvant (Difco) without pertussis toxin.
EAE was assessed by a clinical score of disability: 1, limp tail; 2, hind-limb weakness; 3, partial hind-limb 
paralysis; 4, complete hind-limb paralysis; and 5, moribund state. 
 
Mixed bone marrow chimeras.  B6.Ly5.1 (CD45.1
+
) congenic hosts were lethally irradiated with 1300 Rad split 
into two doses and reconstituted by tail vein injection of 4x10
6
 bone marrow cells.  Cells were a 50:50 mix of 
B6.Ly5.1 WT (CD45.1
+
) and STAT6
-/-
 (CD45.2
+
) bone marrow.  Mice were allowed to reconstitute for 6 weeks 
prior to use.  Expression of CD45.1 or CD45.2 was used to distinguish WT and STAT6
-/-
 cells from the same 
animal for analysis.   
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Cell isolation.  Mice were anesthetized with isoflurane.  Mice were perfused with PBS through the left 
ventricle.  Draining lymph nodes and spleens were isolated, and a single-cell suspension was generated by 
passing cells through a 70-µm mesh filter.  For collection of CNS mononuclear cells, brains were dissected 
from the skull, and spinal cords were flushed from the spinal column with PBS.  Tissues were homogenized 
with an 18G needle and syringe in a solution containing 1 mg/ml collagenase A (Roche) and 1 mg/ml DNase 
1 (Sigma-Aldrich) in HBSS and incubated at 37°C for 20 minutes.  Mononuclear cells were separated from 
myelin with a 27% Percoll gradient (GE Healthcare).   
 
Flow cytometry.  Mononuclear cells were labelled with fixable viability dye (eFluor506 or eFluor780, 
eBioscience), blocked with anti-CD16/32 (Clone 2.4G2, hybridoma), and stained with fluorescent antibodies.  
For intracellular staining, cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% saponin, and 
stained with fluorescent antibodies.  Antibodies for CD62L (Clone MEL-14) and Ly6G (Clone 1A8) were 
obtained from BD Biosciences.  The following antibodies were obtained from eBioscience: CD45 (Clone 30-
F11), CD11b (Clone M1/70), CD11c (Clone N418), NOS2 (Clone CXNFT), CD44 (Clone IM7), CD4 (Clones 
RM4-5, GK1.5), MHC-II (Clone AF6-120.1), CD40 (Clone HM40-3), CD80 (Clone 16-10A1), CD86 (Clone 
GL1).  Antibodies were conjugated to FITC, PE, PeCy7, APC, APC-Cy7, PerCP-Cy5.5, PerCP-eFluor710, 
PE/Dazzle 594, eFluor450, or PE-eFluor610.  Arginase was stained with FITC-conjugated antibody (IC5868F, 
R&D Systems) or with unconjugated antibody (AF5858, R&D Systems) and an AlexaFluor 647-conjugated 
donkey anti-sheep secondary (ThermoFisher).  Data was acquired using a FACSCanto II flow cytometer or 
FACSAria III flow sorter (BD Biosciences) and analyzed with FlowJo software (Treestar).  Cells were sorted 
with a FACSAria III flow sorter (BD Biosciences). 
 
Quantitative real-time PCR.  Sorted cells were resuspended in RLT buffer, and RNA was isolated with the 
RNeasy Mini Kit (Qiagen).  cDNA was generated by reverse transcription with the High Capacity cDNA 
Reverse Transcription Kit (Life Technologies).  Quantitative real-time PCR (qRT-PCR) was performed on an 
iQ Thermocycler (Bio-Rad) using the iQ SYBR Green Supermix.  Relative gene expression was determined 
with the ∆CT method with normalization to Actb. 
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Ex vivo cultures.  For purification of naïve CD4+ T cells, lymph nodes and spleen were collected from naïve 
2D2 TCR transgenic mice, and CD4
+
 T cells were enriched by positive selection with magnetic beads 
(Miltenyi).  To further isolate naïve T cells, cells were sorted for live CD4
+
CD44
-
CD62L
+
 T cells.  For 
purification of memory T cells, mononuclear cells from the CNS were flow sorted for live CD45
+
CD11b
-
CD3
+
CD4
+
MHC-II
- 
T cells.  T cells were labeled with CFSE according the manufacturer’s instructions 
(ThermoFisher).  Myeloid cell populations were sorted with markers as indicated in the text.  Myeloid cells and 
T cells were co-cultured for 96 hours at a ratio of 1:20 (typically 5,000 myeloid cells with 95,000 T cells) in the 
presence or absence of myelin antigen (MOG35-55 peptide [Biosynthesis]).   
 
Multiplex immunoassays.  Cell culture supernatants were analyzed with the Milliplex Mouse Th17 Cytokine 
Panel (EMD Millipore) using the Bio-Plex 200 System (Bio-Rad).  Values below the reported level of detection 
of the assay (minDC) were assigned a value of 0.5*minDC for statistical analysis and represented on graphs 
as not detectable (n.d.). 
 
Immunohistochemistry on MS brain tissue.  Human CNS tissue was obtained at autopsy according to an 
Institutional Review Board-approved protocol at Yale University. CNS tissue was obtained from 4 subjects 
with MS and a total of 5 chronic active white matter lesions were examined. Lesions were identified as 
“chronic active” according to the classification proposed by Bruce Trapp
37
.  Specifically, lesions were 
characterized by ongoing demyelination at the lesion rim, with dense infiltration of CD68-positive myeloid cells 
that contained myelin degradation products. The lesion center was demyelinated but still contained lipid-
positive myeloid cells. Post mortem intervals were between 5.5 and 24 hrs. Brain tissue was fixed with 10% 
formalin for 2 to 4 weeks and embedded in paraffin.  Formalin-fixed, paraffin-embedded (FFPE) sections were 
cut, quenched with hydrogen peroxide and blocked with normal serum, incubated with primary antibodies 
overnight and finally processed with the appropriate biotinylated secondary antibody and avidin/biotin staining 
kit with diaminobenzidene as chromogen (Vector ABC Elite Kit and DAB Kit, Vector Laboratories), and 
counterstained with haematoxylin. The following antibodies were used in this study: MBP (Rabbit polyclonal, 
Dako A0623), CD68 (Mouse monoclonal, Dako M0876), iNOS (Rabbit polyclonal, Novus NB 120-15203), 
CD206 (Mouse polyclonal, Abcam ab117644), and Iba-1 (Goat polyclonal, Abcam ab5076).  Adequate 
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acquired with a Leica DM5000 B microscope using a Leica colour camera DFC310 Fx and the Leica 
Application Suite (version 4.2.0) imaging software. For fluorescence images, sections were incubated with 
fluorescent-labelled secondary antibodies and subsequently treated with 0.7% Sudan Black in ethanol and 
CuSO4 to quench auto- fluorescence. Sections were counterstained with DAPI and mounted with VectaShield 
mounting medium (VectaShield Kit, Vector Laboratories). Images were acquired with an UltraVIEW VoX 
(Perkin Elmer) spinning disc confocal Nikon Ti-E Eclipse microscope. Image acquisition, visualization and 
quantification were performed using the Volocity 6.3 soft- ware (Improvision). Images were processed with the 
ImageJ software (Schneider et al., 2012). For 3D Surface plots, colors were split into red, green and blue, and 
only the red color images were processed further. Background was removed by setting an appropriate 
threshold and the resulting image was processed with the “Interactive Surface Plot v2.4” ImageJ plug-in. 
 
Statistics.  Statistical analysis was performed using paired or un-paired, 2-tailed Student’s t test, as indicated 
in the legends. 
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RESULTS 
Macrophage polarization shifts from the core to the rim of MS lesions 
In order to characterize the polarization state of CD68
+
 macrophage in chronic active MS lesions, we 
immunolabelled brain tissue sections from 4 patients (Table 1) with antibodies against iNOS and CD206, the 
standard markers of classically and alternatively activated human myeloid cells, respectively
2,14,38,39
.  MS 
lesions tend to grow centrifugally over time, with inflammatory activity gradually moving outward. Chronic 
active lesions have a relatively quiescent and hypocellular lesion center, due to waning of the earlier 
inflammatory response, surrounded by a rim of macrophages with early myelin degradation products, 
signifying ongoing demyelination
37
.  We found that a high percentage of CD68
+
 macrophages at the lesion rim 
were iNOS
+
, while relatively few macrophages expressed CD206 (Figure 1A-D). Conversely, the ratio of 
CD206
+
 cells was higher than iNOS
+
 cells among those macrophages in the center of the lesion.  We 
detected iNOS/CD206 double positive macrophages in all 5 MS lesions, which were most numerous in the 
lesion center (Figure 1E).  Consistent with our results, Vogel and colleagues discovered foamy macrophages 
and activated microglia in a panel of active MS lesions that consistently co-expressed AAMC and CAMC 
markers
2
.  
 
Arg1 is expressed by a subset of CNS-infiltrating myeloid cells at peak EAE 
Next, we investigated the phenotypes of CNS myeloid cells during the course of EAE.  We found that 
the myeloid cells that accumulate in the CNS do not reliably express CD206 at onset, peak, or late time points 
of EAE, but a subset of splenic myeloid cells inconsistently expressed CD206 at high levels (data not shown).  
Since Arg1 is commonly used to identify murine AAMC
12
, we measured expression of iNOS and Arg1 in 
inflammatory cells isolated from the spinal cord at serial time points following active immunization with myelin 
peptide.  We detected iNOS, but not Arg1, in mononuclear cells isolated from the spinal cord at clinical onset 
(Figure 2A).  In contrast, at peak disease we detected Arg1, but not iNOS, in the CNS myeloid cells.  Arg1 
was expressed by CD45
hi
CD11b
+
 infiltrating myeloid cells and CD45
int
CD11b
int
 resident microglia, but not by 
CD45
+
CD11b
-
 lymphoid cells or CD45
-
 nonhematopoietic cells (Figure 2B).  The CD45
hi
CD11b
+
 myeloid 
subset was further divided into Ly6G
+
 neutrophils, CD11c
-
 monocytes/ macrophages (MΦ), and CD11c
+
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t dendritic cells (DC).  Arg1 was expressed by a significant percent of the infiltrating MΦ and DC, but not by 
neutrophils.  At clinical onset, expression of iNOS followed a similar pattern both in spinal cord and brain 
mononuclear cells (data not shown).  Arg1
+
 and iNOS
+
 myeloid cells were restricted to the CNS as no Arg1
+
 
or iNOS
+
 cells were detected in the spleen, draining lymph nodes or blood (data not shown).  
We sorted Arg1
+
 and Arg1
-
 MΦ (CD45
hi
CD11b
+
Ly6G
-
CD11c
-
) or DC (CD45
hi
CD11b
+
Ly6G
-
CD11c
+
) 
from the CNS of Arg1-eYFP reporter mice
35
 during peak stage EAE, and we measured the expression of 
candidate genes by quantitative RT-PCR.  Genes associated with in vitro generated AAMC, including Ym1 
and Mrc1, were enriched in Arg1
+
 CNS DC and MΦ, compared with their Arg1
-
 counterparts, while CAMC-
related genes (iNOS, IL-1β, IL-6) were unchanged or reduced (Figure 2C).  The genetic profiles of Arg1
+
 and 
Arg1
-
 CNS myeloid cells did not precisely mirror those of in vitro generated AAMC and CAMC, respectively.  
For example, mRNA encoding the AAMC-associated cytokines IL-10 and TGFβ1 were expressed at similar 
levels Arg1
-
 and Arg1
+
 cells, and the CAMC-associated cytokine TNFα was expressed at relatively high levels 
in the CD11c
-
Arg1
+
 cohort.  Reminiscent of these results, an Arg1
+
 CNS myeloid subset with a mixed gene 
profile was recently described in traumatic brain injury
40
, which may signify a distinct myeloid cell phenotype 
induced within the CNS microenvironment.   
 
Arg1
+
 myeloid cells accumulate in the CNS independent of STAT6 
STAT6 has been identified as a critical regulator of Arg1 expression in BMDMs in response to IL-4 
and IL-13 in vitro
41
.  To determine whether STAT6 is also critical for the accumulation of Arg1
+
 CNS myeloid 
cells during EAE, we constructed mixed bone marrow chimeric mice by reconstituting lethally irradiated WT 
mice with a combination of STAT6
-/-
 and WT bone marrow cells.  Brain and spinal cord mononuclear cells 
were isolated from individual chimeric mice at peak EAE for flow cytometric analysis.  The frequency of Arg1
+
 
cells was modestly reduced among STAT6
-/-
, compared with WT, myeloid cells isolated from the same CNS 
tissue (Figure 2D).  Nonetheless, the accumulation of Arg1
+
 CNS myeloid cells was largely preserved in the 
absence of STAT6.   
 
Myeloid cells shift from iNOS to Arg1 expression during the evolution of adoptively transferred and 
relapsing remitting EAE 
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modulate innate immune cells.  In order to determine how iNOS and Arg1 expression evolves in CNS myeloid 
cells during EAE in the absence of adjuvant, we utilized an adoptive transfer model.  Naïve C57BL/6 mice 
were injected with myelin-primed syngeneic Th17 cells, and CNS mononuclear cells were isolated at serial 
time points for analysis by flow cytometry.  Similar to our observations in the active immunization model, 
iNOS
+
Arg1
-
 cells were prominent during the preclinical stage and at clinical onset, while iNOS
-
Arg1
+
 cells 
were prominent during peak and late disease (Figure 3A).  A population of iNOS
+
Arg1
+
 CNS myeloid cells 
also emerged at clinical onset but had contracted by peak EAE.  This dynamic shift in the expression of iNOS 
and Arg1 occurred in CNS-infiltrating MΦ and DC, as well as in CD45
int
CD11b
int
 resident microglia (Figure 
3B).   
Next, we used a relapsing remitting model of EAE in SJL mice to determine whether myeloid cells 
undergo cyclical shifts in iNOS and Arg1 expression through multiple relapses.  We observed that an 
iNOS
+
Arg1
-
 subset accumulated immediately prior to the first exacerbation, contracted during peak disease, 
and rebounded at relapse (Figure 3C-E). In contrast, an iNOS
-
Arg1
+
 subset expanded between the preclinical 
stage and peak EAE, waned during remission, and re-emerged at the peak of relapse.  Collectively, these 
results demonstrate that a shift in myeloid cell phenotype parallels clinical exacerbations and remissions/ 
plateaus and is consistent across multiple models of EAE. 
 
Individual myeloid cells convert from iNOS to Arg1 expression 
Khoury and colleagues described immunosuppressive Ly6C
hi
 monocytes that expand in the periphery, 
accumulate in the CNS during EAE, and have the potential to differentiate into either iNOS
+
 or Arg1
+
 cells 
upon ex vivo culture with different polarizing factors
20
.  As shown in Figures 1 and 3, we detected myeloid 
cells in MS and EAE lesions that co-express AAMC and CAMC markers.  It is unclear if these cells represent 
a distinct, stable lineage or an intermediate stage during the transition between polarized subsets.  The 
experiments in Figures 3 demonstrate the evolving characteristics of CNS myeloid cells on a population level; 
however, they do not address plasticity at the level of individual cells.  To this end, we permanently labelled 
iNOS
+
 cells and their descendants by crossing NOS2-TdTomato-Cre reporter mice
36
 with Rosa26-LSL-eYFP 
reporter mice  to generate iNOS fate-mapping mice (iNOS
FM
).  Disease was induced in these mice by 
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mapping mice at peak EAE expressed eYFP, indicative of previous expression of iNOS (iNOS
FM+
) (Figure 4A-
B).  At this point, iNOS protein is no longer detectable.  Approximately 45% of the iNOS
FM+
 subset co-
expressed Arg1 (Figure 4C), demonstrating that individual CNS-infiltrating myeloid cells are capable of 
transitioning from expression of iNOS to expression of Arg1 during the course of disease. However, Arg1 
expression is not absolutely dependent on prior expression of iNOS since ~15% of the iNOS
FM-
 cells were 
also Arg1
+
.   Notably, a higher percentage of Arg1
+
 than Arg1
-
 cells were derived from iNOS
FM+
 precursors 
(33% versus 9%).  These data demonstrate that Arg1-expressing cells may be derived from iNOS-expressing 
cells or from iNOS-naïve cells. 
 
Arg1-expressing CNS myeloid cells are inefficient antigen presenting cells 
DCs have been identified as potent antigen presenting cells (APC) in the CNS during EAE
7,42
.  We 
sought to compare the APC function of Arg1
+
 versus Arg1
-
 CNS DC by measuring the ability of each subset to 
promote myelin-specific T cell proliferation ex vivo.   Sorted CNS DC subsets were co-cultured with naïve 2D2 
CD4
+
 T cells, which bear a transgenic T cell receptor specific for myelin oligodendrocyte glycoprotein peptide 
(MOG35-55), in the presence of myelin peptide.  Compared with their Arg1
-
 counterparts, Arg1
+
 CNS DC were 
inefficient in promoting the proliferation of, or cytokine production by, myelin-specific T cells (Figure 5A-B).  
Similar results were obtained when MOG1-125 protein was used as the recall antigen (data not shown).  The 
majority of CD4
+
 T cells within the CNS during EAE are CD44
+
CD62L
lo
 effector cells.  In order to simulate 
antigen presentation within the CNS more closely, we next isolated CD4
+
 effector T cells from the spinal cords 
of mice at peak EAE and co-cultured them with Arg1
+
 or Arg1
-
 CNS DC.  Similar to naïve 2D2 T cells, the 
CD4
+
 effector T cells proliferated and secreted cytokines at reduced levels in response to antigen 
presentation by Arg1
+
 versus Arg1
-
 CNS DC (Figure 5C-D). The poor APC capacity of Arg1
+
 CNS DC did not 
appear to be due to low expression of MHC-II or co-stimulatory molecules (Figure 5E-F).  Essentially all of the 
Arg1
+
 and Arg1
-
 CNS DC expressed MHC-II, though Arg1
+
 cells expressed a slightly lower level than their 
Arg1
-
 counterparts.  Arg1
+
 CNS DC expressed similar levels of the co-stimulatory marker CD40 and slightly 
higher levels of CD80 and CD86 compared with Arg1
-
 CNS DC.  Arginase enzyme activity has been shown to 
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cultures of T cells with Arg1
+
 CNS myeloid cells did not rescue T cell activation (data not shown).   
We next investigated whether Arg1
+
 CNS myeloid cells are immunosuppressive or simply 
incompetent APCs.    Arg1
+
 CNS myeloid cells did not induce 2D2 T cells to upregulate FoxP3 (data not 
shown) or to produce IL-10 (Figures 5B, D). Furthermore, the addition of Arg1
+
 CNS myeloid cells to co-
cultures of Arg1
-
 myeloid cells and 2D2 T cells did not impede antigen presentation by the Arg1
-
 cells (data 
not shown).  Hence, we concluded that Arg1
+
 cells are intrinsically poor APC but do not actively block T cell 
activation by competent APC.     
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DISCUSSION 
Collectively, the data presented in our study demonstrate the heterogeneity and plasticity of myeloid 
cells within the CNS in MS and EAE.  We identified an Arg1
+
 CNS myeloid population during the peak and 
later stages of EAE which is deficient in the capacity to activate myelin-specific T cells. The appearance of 
Arg1
+
 myeloid cells in the CNS immediately prior to disease remission was consistent across multiple disease 
induction methods (active and adoptive) as well as across mouse strains (C57Bl/6 and SJL).  CNS Arg1
+
 DC 
were not immunosuppressive in the sense that they did not actively suppress T cell activation by their 
immunocompetent Arg1
-
 counterparts.  Nevertheless, the poor antigen presenting ability of these myeloid 
cells may passively contribute to the resolution of inflammation, and hence to clinical remission, following 
peak disease.  The mechanism underlying ineffective antigen presentation by CNS Arg1
+
 myeloid cells 
remains to be elucidated.   We are currently interrogating the efficiency of myelin antigen loading on MHC-II 
molecules in CNS DC subsets.  It is also possible that the Arg1
+
 cells play an immunoregulatory or pro-
regenerative role independent of T cell activation.  Although the Arg1
+
 cells do not produce IL-10 and express 
comparable levels of TGFβ1 to Arg1
-
 cells, we are currently investigating whether they secrete other 
regulatory molecules.  CNS AAMC may play a role in ameliorating the clinical course by clearing debris
23,24
 
and/or releasing trophic factors
25
. 
Arg1
+
 CNS myeloid cells differ from in vitro polarized AAMC in that they differentiate in the absence of 
STAT6, express low levels of CD206 and high levels of MHC-II, and have a distinct genetic profile. The 
factors that drive their polarization in vivo are a subject of ongoing research.  Candidates include HIF1α and 
PPARγ, which have been shown to promote AAMC differentiation in other experimental systems
45,46
.  
Alternatively, studies with primary human macrophages suggest that ingestion of myelin could trigger their 
development
19
.  Unexpectedly, we found that the Arg1
+
 CNS myeloid cells that accumulate in the CNS during 
EAE are derived, in part, from iNOS
+
 precursors.  Although plasticity of CAMC and AAMC has previously 
been demonstrated in other experimental systems on the population level, the current study is the first to our 
knowledge to directly demonstrate the transition of CNS myeloid cells from iNOS to Arg1 expression in vivo 
on the single cell level.  Furthermore, during the transition from iNOS to Arg1 expression, CNS myeloid cells 
entered an intermediary stage characterized by expression of both markers.  The demonstration by us and 
Page 14 of 31
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t 	others2 that myeloid cells in MS lesions also co-express CAMC and AAMC markers raises the possibility that 
they undergo a dynamic transformation from a pro- to a non-inflammatory state.  Such a transformation is 
further suggested by the increasing gradient of iNOS versus CD206 expression in macrophages extending 
from the active rim to the quiescent center of chronic active MS lesions.    
Second generation disease modifying therapies (DMT) in MS suppress clinical exacerbations by 
depleting peripheral lymphocytes or blocking their trafficking to the CNS.  While these reagents are highly 
effective in many individuals with relapsing-remitting MS, they are not cures, with up to 30% non-response 
rates.  Furthermore, DMT currently used in the clinic are generally ineffective in progressive forms of MS.   
Myeloid cells and related factors have been under-utilized as candidate therapeutic targets in MS clinical 
trials.  This is particularly relevant to secondary progressive MS, since numerous studies point to 
dysregulation of the innate arm of the immune system and, in particular, cells of the myeloid lineage as a 
distinctive feature of that stage of disease
47–50
.  The current findings suggest an opportunity for slowing, or 
even halting, progressive disability in patients with MS via the development of novel therapeutics that 
suppress pathogenic myeloid subsets in a targeted manner and/or promote their conversion to a non-
inflammatory phenotype. 
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t FIGURE LEGENDS 
Figure 1.  CD206
+
 and iNOS
+
 macrophages are distributed from the center to the rim of active MS 
lesions. (A) Chronic active MS lesion immunolabeled for myelin basic protein (MBP) and CD68. (B) Cross 
sections of the same lesion, extending from the lesion center to the lesion rim, immunolabeled for CD206 and 
iNOS. (C) Quantification of iNOS
+
 and CD206
+
 cells at the lesion center and lesion rim. The number of cells is 
expressed as a percentage of CD68
+
 cells. N=5 lesions quantified.  *P<0.05, **P<0.01 by paired, 2-tailed 
Student’s t test.  (D) Surface plots of sections in B with the number of stained cells expressed as height, 
processed with the “Interactive Surface Plot v2.4” ImageJ plug-in. (E) Representative immunofluorescent 
labeling for CD206 (white), iNOS (magenta), and Iba1 (yellow).  Scale bars indicate 150 µM (A); 100 µM (B) 
and 10 µM (E).  
 
Figure 2. Arg1 expression defines a distinct myeloid cell population that accumulates in the CNS 
during later stages of EAE.  (A, B) EAE was induced in mice by active immunization with myelin peptide.  
Inflammatory cells were isolated from the CNS at the onset or peak of clinical disability.  Representative 
intracellular staining of Arg1 and iNOS in CNS immune cells from WT mice gating on (A) all viable cells at 
onset or peak or (B) cell subsets at peak disease.  (C) Arg1
+
 and Arg1
-
 myeloid cells were flow sorted from 
the CNS of Arg1-eYFP reporter mice.  M1 and M2 related transcripts were measured by qRT-PCR.  Data are 
represented as the ratio of gene expression in Arg1
+
 cells over Arg1
-
 cells. (D)  Inflammatory cells were 
isolated from the CNS of STAT6
-/-
:WTWT mixed bone marrow chimeric mice at the peak of EAE.  
Representative flow and quantification of intracellular staining of Arg1 and iNOS in WT or STAT6
-/-
 cells, 
gated on the CD45
hi
CD11b
+
Ly6G
- 
population. Percentages are Arg1
+
 cells among WT or STAT6
-/-
 CNS 
myeloid cells isolated from individual chimeric mice. Connected dots indicate cells derived from the same 
mouse. *P<0.05, **P<0.01, ***P<0.001 and n.s. = P>0.05, by paired, 2-tailed Student’s t test.  Data are 
representative of at least 2 experiments.  N=3-5 mice per group.  All values are mean ± SEM. 
 
Figure 3. Myeloid cells shift from iNOS to Arg1 expression in adoptive transfer and relapsing models 
of EAE.  (A, B) EAE was induced by adoptive transfer of WT myelin-primed Th17 cells into naïve syngeneic 
hosts.  CNS inflammatory cells were isolated at serial time points and analyzed by flow cytometry.  (A) 
Representative intracellular staining of Arg1 and iNOS, gating on the CD45
hi
CD11b
+
Ly6G
-
 population.  (B) 
Percentages of CD45
hi
CD11b
+
CD11c
-
 MΦ, CD45
hi
CD11b
+
CD11c
+ 
DC and CD45
mid
CD11b
+
CD11c
-
 microglia 
expressing iNOS and/or Arg1 in naïve mice (N) and in mice with EAE during the pre-clinical (PC), onset (O), 
peak (P), and late (L) stages of disease. (C-E) EAE was induced in SJL mice by active immunization with 
PLP139-151 peptide, and CNS inflammatory cells were collected at serial time points, including onset (O), peak 
of first episode (P), remission (Rem), and relapse (Rel). Cells were also collected from mice that experienced 
an initial exacerbation followed by remission but did not subsequently relapse (No Rel).  (C) Representative 
dot plots of intracellular iNOS and Arg1 expression gating on the CD45
hi
CD11b
+
Ly6G
-
 population. (D) 
Representative relapsing-remitting clinical course of SJL mice.  (E) Percentages of CD45
hi
CD11b
+
Ly6G
-
 CNS 
myeloid cells expressing iNOS and/or Arg1 at serial time points.  Data are representative of at least 2 
experiments.  N=3-5 mice per time point.  All values are mean ± SEM. 
 
Figure 4. Arg1-expressing CNS myeloid cells are derived, in part, from iNOS-expressing precursors.  
EAE was induced in mice by adoptive transfer of WT myelin-primed Th17 cells.  CNS inflammatory cells were 
analyzed by flow cytometry.  (A-C) Inflammatory cells were isolated from the spinal cords of iNOS
FM
 mice at 
peak disease. (A-B) Representative dot plots showing iNOS
FM
 and (A) Arg1 or (B) iNOS expression, gated on 
CD45
hi
CD11b
+
Ly6G
-
 myeloid cells. (C) Percentages of CNS myeloid cell subpopulations defined according to 
iNOS
FM
 and Arg1 expression.  Subpopulations were initially segregated based on expression of iNOS
FM
 (left) 
or Arg1 (right).  Data are representative of at least 2 experiments.  N=3-5 mice per group. Mean values are 
shown.   
 
Figure 5. Arg1
+
 cells are deficient at antigen presentation. EAE was induced in Arg1-eYFP reporter mice 
by active immunization with myelin peptide, and immune cells were isolated from the CNS at peak disease.  
Arg1
+
 and Arg1
-
 CD45
hi
CD11b
+
Ly6G
-
CD11c
+
 myeloid cells were flow sorted and co-cultured with MOG-
reactive T cells in the presence of myelin peptide (MOG35-55).  (A-B)  CNS myeloid cell subsets were co-
cultured with CD44
-
CD62L
+
 CD4
+
 T cells from naïve 2D2 TCR transgenic mice. (C, D) CNS myeloid subsets 
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t were co-cultured with CD4+ T cells isolated from the CNS of actively immunized WT mice at the peak of EAE. Graphs show (A, C) proliferation measured by CFSE dilution and (B, D) cytokine levels in culture 
supernatants, measured by multiplex bead assay.   (E, F) MHC-II and co-stimulatory marker expression were 
measured by flow cytometry on Arg1
+
 and Arg1
-
 CD45
hi
CD11b
+
Ly6G
-
CD11c
+
 myeloid cells from the spinal 
cord at the peak of disease. (E) MHC-II expression quantified as both a percentage and by geometric MFI. (F) 
Co-stimulatory marker expression quantified by geometric MFI.  *P<0.05, **P<0.01, and n.s. = P>0.05, by 
paired, 2-tailed Student’s t test.  Data are representative of at least 2 experiments.  N=3-5 mice per group.   
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Table 1: Clinical data of MS patients included in this study 
Case Age Gender Disease Course Disease Duration 
Post-mortem 
Interval 
1 42 Male RRMS 20 yrs 5.5 hrs 
2 37 Male RRMS 15 yrs 24 hrs 
3 50 Female RRMS 10 yrs 6 hrs 
4 63 Female SPMS unknown 8 hrs 
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Figure 1.  CD206+ and iNOS+ macrophages are distributed from the center to the rim of active MS lesions. 
(A) Chronic active MS lesion immunolabeled for myelin basic protein (MBP) and CD68. (B) Cross sections of 
the same lesion, extending from the lesion center to the lesion rim, immunolabeled for CD206 and iNOS. (C) 
Quantification of iNOS+ and CD206+ cells at the lesion center and lesion rim. The number of cells is 
expressed as a percentage of CD68+ cells. N=5 lesions quantified.  *P<0.05, **P<0.01 by paired, 2-tailed 
Student’s t test.  (D) Surface plots of sections in B with the number of stained cells expressed as height, 
processed with the “Interactive Surface Plot v2.4” ImageJ plug-in. (E) Representative immunofluorescent 
labeling for CD206 (white), iNOS (magenta), and Iba1 (yellow).  Scale bars indicate 150 µM (A); 100 µM (B) 
and 10 µM (E).  
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Figure 2. Arg1 expression defines a distinct myeloid cell population that accumulates in the CNS during later 
stages of EAE.  (A, B) EAE was induced in mice by active immunization with myelin peptide.  Inflammatory 
cells were isolated from the CNS at the onset or peak of clinical disability.  Representative intracellular 
staining of Arg1 and iNOS in CNS immune cells from WT mice gating on (A) all viable cells at onset or peak 
or (B) cell subsets at peak disease.  (C) Arg1+ and Arg1- myeloid cells were flow sorted from the CNS of 
Arg1-eYFP reporter mice.  M1 and M2 related transcripts were measured by qRT-PCR.  Data are represented 
as the ratio of gene expression in Arg1+ cells over Arg1- cells. (D)  Inflammatory cells were isolated from 
the CNS of STAT6-/-:WT◊WT mixed bone marrow chimeric mice at the peak of EAE.  Representative flow 
and quantification of intracellular staining of Arg1 and iNOS in WT or STAT6-/- cells, gated on the 
CD45hiCD11b+Ly6G- population. Percentages are Arg1+ cells among WT or STAT6-/- CNS myeloid cells 
isolated from individual chimeric mice. Connected dots indicate cells derived from the same mouse. 
*P<0.05, **P<0.01, ***P<0.001 and n.s. = P>0.05, by paired, 2-tailed Student’s t test.  Data are 
representative of at least 2 experiments.  N=3-5 mice per group.  All values are mean ± SEM.  
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Figure 3. Myeloid cells shift from iNOS to Arg1 expression in adoptive transfer and relapsing models of 
EAE.  (A, B) EAE was induced by adoptive transfer of WT myelin-primed Th17 cells into naïve syngeneic 
hosts.  CNS inflammatory cells were isolated at serial time points and analyzed by flow cytometry.  (A) 
Representative intracellular staining of Arg1 and iNOS, gating on the CD45hiCD11b+Ly6G- population.  (B) 
Percentages of CD45hiCD11b+CD11c- MΦ, CD45hiCD11b+CD11c+ DC and CD45midCD11b+CD11c- 
microglia expressing iNOS and/or Arg1 in naïve mice (N) and in mice with EAE during the pre-clinical (PC), 
onset (O), peak (P), and late (L) stages of disease. (C-E) EAE was induced in SJL mice by active 
immunization with PLP139-151 peptide, and CNS inflammatory cells were collected at serial time points, 
including onset (O), peak of first episode (P), remission (Rem), and relapse (Rel). Cells were also collected 
from mice that experienced an initial exacerbation followed by remission but did not subsequently relapse 
(No Rel).  (C) Representative dot plots of intracellular iNOS and Arg1 expression gating on the 
CD45hiCD11b+Ly6G- population. (D) Representative relapsing-remitting clinical course of SJL mice.  (E) 
Percentages of CD45hiCD11b+Ly6G- CNS myeloid cells expressing iNOS and/or Arg1 at serial time 
points.  Data are representative of at least 2 experiments.  N=3-5 mice per time point.  All values are mean 
± SEM.  
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Figure 4. Arg1-expressing CNS myeloid cells are derived, in part, from iNOS-expressing precursors.  EAE 
was induced in mice by adoptive transfer of WT myelin-primed Th17 cells.  CNS inflammatory cells were 
analyzed by flow cytometry.  (A-C)  Inflammatory cells were isolated from the spinal cords of iNOSFM mice 
at peak disease. (A-B) Representative dot plots showing iNOSFM and (A) Arg1 or (B) iNOS expression, gated 
on CD45hiCD11b+Ly6G- myeloid cells. (C) Percentages of CNS myeloid cell subpopulations defined 
according to iNOSFM and Arg1 expression.  Subpopulations were initially segregated based on expression of 
iNOSFM (left) or Arg1 (right).  Data are representative of at least 2 experiments.  N=3-5 mice per group. 
Mean values are shown.    
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Figure 5. Arg1+ cells are deficient at antigen presentation. EAE was induced in Arg1-eYFP reporter mice by 
active immunization with myelin peptide, and immune cells were isolated from the CNS at peak 
disease.  Arg1+ and Arg1- CD45hiCD11b+Ly6G-CD11c+ myeloid cells were flow sorted and co-cultured with 
MOG-reactive T cells in the presence of myelin peptide (MOG35-55).  (A-B)  CNS myeloid cell subsets were 
co-cultured with CD44-CD62L+ CD4+ T cells from naïve 2D2 TCR transgenic mice. (C, D) CNS myeloid 
subsets were co-cultured with CD4+ T cells isolated from the CNS of actively immunized WT mice at the 
peak of EAE. Graphs show (A, C) proliferation measured by CFSE dilution and (B, D) cytokine levels in 
culture supernatants, measured by multiplex bead assay.   (E, F) MHC-II and co-stimulatory marker 
expression were measured by flow cytometry on Arg1+ and Arg1- CD45hiCD11b+Ly6G-CD11c+ myeloid 
cells from the spinal cord at the peak of disease. (E) MHC-II expression quantified as both a percentage and 
by geometric MFI. (F) Co-stimulatory marker expression quantified by geometric MFI.  *P<0.05, **P<0.01, 
and n.s. = P>0.05, by paired, 2-tailed Student’s t test.  Data are representative of at least 2 
experiments.  N=3-5 mice per group.    
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tCase Age Gender Disease Course Disease duration Post-mortem Interval1 42 Male RRMS 20 yrs 5.5 hrs
2 37 Male RRMS 15 yrs 24 hrs
3 50 Female RRMS 10 yrs 6 hrs
4 63 Female SPMS unknown 8 hrs
Table 1: Clinical data of MS patients included in this study
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